In the medical field, the quantity of information now doubles every 73 days, and faced with this explosion, the major generalist language models, capable of producing rapid summaries, struggle to guarantee the precision and reliability required by caregivers. It is in this breach that a new generation of specialized tools emerges, including Juisc, a French startup that has chosen to build its own AI exclusively trained on scientific publications.
The challenge of the startup is to transform a sprawling corpus by knowingly exploitable by practitioners, hospitals and laboratories. The approach differs radically from that of generalist LLMs which favor exhaustiveness and versatility, when juisci relies on depth, verifiability and daily use. The application offers intelligible summaries, infographics, podcasts or even videos, integrated into a mobile interface designed to integrate into medical routine.
Robin Roumengas, co -founder and CEO, sums up the philosophy of society: “Health professionals do not need more information, they need clear, fast and reliable access to science. With Juisci, we want to give them time and confidence, while helping organizations to enhance scientific data at the service of medical progress. »»
The relevance of this approach has won over 200,000 users in sixty countries, who now use the solution, available in ten languages. Thirty institutional and industrial customers, including Sanofi, Takeda, L’Oréal, Royal Canin, the National Academy of Surgery or the European Radio Society, are already based on the platform to accelerate the dissemination of knowledge and strengthen their scientific communication.
JUISCI claims to win up to eight hours each week for a healthcare professional and a twelve multiplication of content production thanks to AI.
Founded in 2021 by Robin Roumengas and Dr. David Luu, then joined in 2024 by an artificial intelligence expert, Juisc has just raised 5.5 million euros in Seed from Ring Capital, Big Pi Ventures, Bpifrance and several strategic business angels. This funding should make it possible to strengthen R&D, to expand teams and prepare international expansion, with a priority objective: the American market.
